- Home
- ADGM vs BLRX Comparison
ADGM vs BLRX Comparison
Compare ADGM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- BLRX
- Stock Information
- Founded
- ADGM 2011
- BLRX 2003
- Country
- ADGM United States
- BLRX Israel
- Employees
- ADGM N/A
- BLRX N/A
- Industry
- ADGM
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ADGM
- BLRX Health Care
- Exchange
- ADGM NYSE
- BLRX Nasdaq
- Market Cap
- ADGM 14.7M
- BLRX 12.2M
- IPO Year
- ADGM N/A
- BLRX 2011
- Fundamental
- Price
- ADGM $0.79
- BLRX $2.94
- Analyst Decision
- ADGM
- BLRX Buy
- Analyst Count
- ADGM 0
- BLRX 2
- Target Price
- ADGM N/A
- BLRX $26.00
- AVG Volume (30 Days)
- ADGM 39.6K
- BLRX 26.6K
- Earning Date
- ADGM 03-31-2025
- BLRX 05-27-2025
- Dividend Yield
- ADGM N/A
- BLRX N/A
- EPS Growth
- ADGM N/A
- BLRX N/A
- EPS
- ADGM N/A
- BLRX N/A
- Revenue
- ADGM $602,000.00
- BLRX $28,940,000.00
- Revenue This Year
- ADGM N/A
- BLRX N/A
- Revenue Next Year
- ADGM N/A
- BLRX N/A
- P/E Ratio
- ADGM N/A
- BLRX N/A
- Revenue Growth
- ADGM 100.67
- BLRX 502.92
- 52 Week Low
- ADGM $0.75
- BLRX $2.85
- 52 Week High
- ADGM $9.34
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- BLRX 37.85
- Support Level
- ADGM N/A
- BLRX $3.01
- Resistance Level
- ADGM N/A
- BLRX $3.61
- Average True Range (ATR)
- ADGM 0.00
- BLRX 0.21
- MACD
- ADGM 0.00
- BLRX 0.01
- Stochastic Oscillator
- ADGM 0.00
- BLRX 11.84
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.